Erbitux Combined With Concomitant Chemotherapy And Radiotherapy For Locoregional Advanced Nasopharyngeal Carcinoma

Objective:to evaluate the short term efficacy and safety of Erbitux combined with concomitant chemotherapy and radiotherapy for locoregional advanced nasopharyngeal carcinoma.Methods:30 patients with pathologically confirmed locally advanced nasopharyngeal carcinoma were randomized to received Erbitux combined with concomitant chemoradiotherapy or concomitant chemoradiotherapy.9 patients were enrolled in the trail arm, and 21 patients in the control arm, the both arm received cisplatin (80mg/m2, w1,4±7) and intensity modulate radiotherapy (IMRT). The prescription dose engaged to GTVnx, GTVnd, CTV1, CTV2 were 66～75.9,66～70,64,54 Gy respectively in 6-7week(1F/day,5F/week,).CTV1 and upper neck were irradiated by IMRT technique. The lower neck and the supraclavicular fossae were irradiated with the conventional technique using an anterior field. Erbitux was administrated to the trail arm at initial dose of 400 mg/m~2, followed by 250 mg/m~2 weekly for the duration of radiotherapy. Treatment-related adverse side effects were evaluated according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE v3.0). Clinical efficacy was record according to Response Evaluation Criteria in Solid Tumors (RECIST).Results:Except acne-like rash and mucositis, most of adverse events were grade 1～2, the difference between two arms was not statistically significant. The local control rate (LCR) of all the patients was 100%,1-year distant metastasis-free survival (DMFS) rates were (5/7)71.4%, (18/21)85.7% respectively, but the difference was not statistically significant (P=0.367).Conclusion:The short term efficacy of Ebitux is excellent, the long term efficacy of Ebitux remains to be verified for the constraints. It is safe for patients to receive Erbitux combined with concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma, and its side effects are tolerable.